全文获取类型
收费全文 | 226927篇 |
免费 | 21266篇 |
国内免费 | 13197篇 |
专业分类
耳鼻咽喉 | 2333篇 |
儿科学 | 3665篇 |
妇产科学 | 1494篇 |
基础医学 | 17253篇 |
口腔科学 | 4409篇 |
临床医学 | 26382篇 |
内科学 | 25580篇 |
皮肤病学 | 2618篇 |
神经病学 | 7771篇 |
特种医学 | 9306篇 |
外国民族医学 | 25篇 |
外科学 | 22839篇 |
综合类 | 53695篇 |
现状与发展 | 53篇 |
一般理论 | 10篇 |
预防医学 | 23721篇 |
眼科学 | 3376篇 |
药学 | 24970篇 |
269篇 | |
中国医学 | 18301篇 |
肿瘤学 | 13320篇 |
出版年
2024年 | 886篇 |
2023年 | 2605篇 |
2022年 | 6670篇 |
2021年 | 9022篇 |
2020年 | 7315篇 |
2019年 | 4832篇 |
2018年 | 5133篇 |
2017年 | 6276篇 |
2016年 | 5553篇 |
2015年 | 9147篇 |
2014年 | 11893篇 |
2013年 | 13867篇 |
2012年 | 20247篇 |
2011年 | 21449篇 |
2010年 | 18379篇 |
2009年 | 16257篇 |
2008年 | 17513篇 |
2007年 | 17116篇 |
2006年 | 15167篇 |
2005年 | 12733篇 |
2004年 | 9201篇 |
2003年 | 8023篇 |
2002年 | 6525篇 |
2001年 | 4905篇 |
2000年 | 3852篇 |
1999年 | 1797篇 |
1998年 | 851篇 |
1997年 | 858篇 |
1996年 | 621篇 |
1995年 | 537篇 |
1994年 | 465篇 |
1993年 | 282篇 |
1992年 | 230篇 |
1991年 | 223篇 |
1990年 | 145篇 |
1989年 | 117篇 |
1988年 | 99篇 |
1987年 | 96篇 |
1986年 | 96篇 |
1985年 | 60篇 |
1984年 | 62篇 |
1983年 | 42篇 |
1982年 | 43篇 |
1981年 | 20篇 |
1980年 | 21篇 |
1978年 | 19篇 |
1975年 | 16篇 |
1974年 | 12篇 |
1973年 | 16篇 |
1972年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
目的探讨谷氨酸是否能够影响腺苷A2A受体对一氧化氮合酶(NOS)活力的调节。方法用1000ng/ml脂多糖(LPS)刺激小胶质细胞,分别加入100nmol/L A2A受体激动剂CGS21680以及不同浓度的谷氨酸(0,1,0,25,0,5mmol/L)干预,观察NOS活力变化。结果LPS诱导NOS活力增高,激活A2A受体可以产生抑制作用;0,25及0.5mmoL/L谷氨酸和A2A受体激动剂同时存在时,NOS活力进一步增高。结论高浓度谷氨酸可逆转腺苷A2A受体激动剂抑制升高NOS活力的作用。 相似文献
53.
54.
Kazunori Aizawa Takeshi Hanaoka Hiroki Kasai Kaoru Kogashi Setsuo Kumazaki Jun Koyama Hiroshi Tsutsui Yoshikazu Yazaki Noboru Watanabe Osamu Kinoshita Uichi Ikeda 《Hypertension research》2006,29(2):123-128
The phosphodiesterase-5 (PDE-5) inhibitor, sildenafil, has been reported to produce sustained pulmonary vasodilatation in patients with pulmonary hypertension (PH). Recently, vardenafil, a more potent and selective PDE-5 inhibitor than sildenafil, has been approved for the treatment of erectile dysfunction. However, the long-term effects of oral vardenafil in patients with PH are unknown. We studied five consecutive patients with PH; one with primary pulmonary hypertension, two with chronic pulmonary thromboembolism, one with Eisenmenger syndrome (ventricular septal defect) and one with secondary pulmonary hypertension after a ventricular septal defect closure operation. In an acute hemodynamic trial, vardenafil (5 mg) significantly decreased both the pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR) with an increase in cardiac output. In a chronic hemodynamic trial, the maintenance dose of vardenafil (10 to 15 mg) for 3 months significantly decreased the PVR, but not the SVR, with a 20.7% reduction of the PVR/ SVR ratio. Plasma brain natriuretic peptide (BNP) levels were also significantly decreased after 3 months. This pilot study demonstrates that long-term oral vardenafil therapy may be a safe and effective treatment for patients with PH. 相似文献
55.
56.
BACKGROUND: Ankle brachial index(ABI)is widely involved in researches and clinical application of peripheral vascular injury of patients with diabetes (DM);however ,the application in cerebral infarction(CI)is rare.OBJECTIVE: To investigate the possible risk factor of cerebral infarction plus peripheral arterial disease(PAD),compare metabolic characteristics of patients who having CI plus PAD or only having CI,and understand the significance of ABI on screening and diagnosing CI plus PAD of lower limb.DESIGN: Contrast observation based on CI patients.SETTING: Deparment of Neurology,Nanxishan Hospital of Guangxi Zhang Autonomous Region.PARTICIPANTS:A total of 124 CI patients were selected from Department of Neurology.Nanxishan Hospital of Guangxi Zhuang Autonomous Region from July 2005 to April 2006,including 72 males and 52 females aged from 45 to 88 years.All patients met the diagnostic criteria of cerebrovascular disease established by National Academic Conference of Cerebrovascular Diseases in 1995 and determined as cerebral infarction with MRI or CT examination.All patients provided informed consent.There were 46 cases(37.2%)with CI plus PAD and 78 cases(62.8%)only with CI.METHODS: Blood pressure of bilateral ankles and upper extremities was measured at plain clinostatism with DINAMAP blood pressure monitor(GE Company).The ratio between average systolic pressure of lateral ankle and average systolic pressure of both upper extremities was regarded as ABI.The normal ABI was equal to or more than 0.9.If ABI<0.9 occurred at one side,patients were diagnosed as PAD.On the second morning after hospitalization,blood was collected to measure fasting blood glucose(FBG),2-hour postprandial blood glucose(PBG2h),glycosylated hemoglobin(HbAlc),triglycerides(TG),total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C)and low-density lipoprotein cholesterol(LDL-C).Among them,blood glucose.lipid and other biochemical markers were measured with enzyme chemistry assay and HbA1c was measured with HbA1c meter based on high liquid phase.Measurement data and enumeration data were compared with t test and Chi-square test.and multiple factors were deat with Logistic regression analysis and multivariate linear regression analysis.MAIN OUTCOME MEASURES: Results of correlation between ABI and metabolic markers with multivariate linear regression analysis;risk factors of CI plus PAD with Logistic regression analysis;comparisons of metabolic markers between PAD and non-PAD patients.RESULTS:All 124 patients with acute CI were involved in the final analysis.①Comparisons of metabolic markers:Levels of serum LDL-C and uric acid(UA)were higher of PAD patients than those of non-PAD patients(t=2.051 9,3.339 1,P<0.05);however,there were no significant differences among other metabolic markers(P>0.05).②Results of multivariate linear regression analysis:PBG2h,LDL.C and UA were obvious correlation with ABI of posterior tibial artery of lower limb and dorsal pedis artery rpartial regression coefficient:-0.231 to-1.010,P<0.05).③Risk factors of CI plus PAD with Logistic regression analysis:Age.Smoking history,sum of CI focus(≥3)and LDL-C were independent risk factor of CI plus PAD(OR=1.524-5.422,P<0.05-0.01 ).CONCLUSION:①Levels of serum LDL-C and UA of patients with CI plus PAD are high.②ABI of lower limbs is correlation with PBG2h,LDL-C and UA.In addition,measuring ABI is beneficial for early diagnosing PAD of lower limbs of patients who have poorly controlled blood glucose,abnormal lipid and poor renal function.③Age,LDL-C and sum of CI focus(≥3)are independent risk factors of CI plus PAD.It is of significance for screening non-PAD patients to evaluate risk degrees and prognosis and select therapeutic methods based on ABI measurement. 相似文献
57.
空军不同机种飞行人员脂肪肝患病率分析 总被引:1,自引:0,他引:1
邹国辉 《中华航空航天医学杂志》2006,17(1):52-53
随着我国人民生活水平的不断提高,脂肪肝在人群中患病率也呈逐步上升的趋势.为此,笔者收集我院1999~2004年入院保健疗养飞行人员体检资料,就脂肪肝在不同机种飞行人员中的患病率分析如下. 相似文献
58.
血小板计数在中晚期肝硬化诊断中的价值 总被引:1,自引:0,他引:1
目的探讨血小板计数在肝硬化方面的诊断价值。方法对本院门诊及住院病人,经确诊的肝硬化患者排除MVC小于80fl病例后分为中、晚期二组进行血小板计数统计并作统计学处理。结果中期肝硬化ALP计数为(143±36)×109/L,低于对照组(181±45)×109/L(p<0·01)。晚期肝硬化组ALP计数(86±28)×109/L,明显低于对照组(p<0·01),有非常显著性差异。结论晚期肝硬化患者血小板计数明显低于正常对照组,建议血小板计数可作为晚期肝硬化的诊断指标之一。 相似文献
59.
Jun Agata Nobuyuki Ura Hideaki Yoshida Yasuyuki Shinshi Haruki Sasaki Masaya Hyakkoku Shinya Taniguchi Kazuaki Shimamoto 《Hypertension research》2006,29(11):865-874
Angiotensin II receptor blockers (ARBs) are widely used for the treatment of hypertension. It is believed that treatment with an ARB increases the level of plasma angiotensin II (Ang II) because of a lack of negative feedback on renin activity. However, Ichikawa (Hypertens Res 2001; 24: 641-646) reported that long-term treatment of hypertensive patients with olmesartan resulted in a reduction in plasma Ang II level, though the mechanism was not determined. It has been reported that angiotensin 1-7 (Ang-(1-7)) potentiates the effect of bradykinin and acts as an angiotensin-converting enzyme (ACE) inhibitor. It is known that ACE2, which was discovered as a novel ACE-related carboxypeptidase in 2000, hydrolyzes Ang I to Ang-(1-9) and also Ang II to Ang-(1-7). It has recently been reported that olmesartan increases plasma Ang-(1-7) through an increase in ACE2 expression in rats with myocardial infarction. We hypothesized that over-expression of ACE2 may be related to a reduction in Ang II level and the cardioprotective effect of olmesartan. Administration of 0.5 mg/kg/day of olmesartan for 4 weeks to 12-week-old stroke-prone spontaneously hypertensive rats (SHRSP) significantly reduced blood pressure and left ventricular weight compared to those in SHRSP given a vehicle. Co-administration of olmesartan and (D-Ala7)-Ang-(1-7), a selective Ang-(1-7) antagonist, partially inhibited the effect of olmesartan on blood pressure and left ventricular weight. Interestingly, co-administration of (D-Ala7)-Ang-(1-7) with olmesartan significantly increased the plasma Ang II level (453.2+/-113.8 pg/ml) compared to olmesartan alone (144.9+/-27.0 pg/ml, p<0.05). Moreover, olmesartan significantly increased the cardiac ACE2 expression level compared to that in Wistar Kyoto rats and SHRSP treated with a vehicle. Olmesartan significantly improved cardiovascular remodeling and cardiac nitrite/ nitrate content, but co-administration of olmesartan and (D-Ala7)-Ang-(1-7) partially reversed this anti-remodeling effect and the increase in nitrite/nitrate. These findings suggest that olmesartan may exhibit an ACE inhibitory action in addition to an Ang II receptor blocking action, prevent an increase in Ang II level, and protect cardiovascular remodeling through an increase in cardiac nitric oxide production and endogenous Ang-(1-7) via over-expression of ACE2. 相似文献
60.
目的 探讨P16、P15、P14基因5'CpG岛在膀胱移行细胞癌中甲基化状态及其临床意义。方法 应用甲基化特异性PCR(methylation—specific PCR,MSP)方法检测40例膀胱移行细胞癌P16、P15、P14基因甲基化程度,χ^2检验分析其甲基化程度与膀胱癌病理分级分期间关系。结果 膀胱移行细胞癌P16、P15、P14 5'CpG岛甲基化扩增阳性化率分别为27.5%、17.5%、35%,而正常膀胱组织中均未检测到三种基因5'CpG岛甲基化。P16、P14基因甲基化与膀胱癌病理分级分期有显著性差异(P〈0.05),P15基因则没有显著性差异(P〉0.05)。结论 P16、P15、P14基因在膀胱癌组织中的甲基化率较高,三种抑癌基因5'CpG岛异常高甲基化,在膀胱癌的发生、发展中具有重要作用。 相似文献